Total Payments
$10,292
2024 Payments
$3,093
Companies
60
Transactions
463
Medicare Patients
2,156
Medicare Billing
$167,605
Payment Breakdown by Category
Food & Beverage$10,006 (97.2%)
Education$285.99 (2.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $10,006 | 459 | 97.2% |
| Education | $285.99 | 4 | 2.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $692.14 | 32 | $0 (2024) |
| Merck Sharp & Dohme LLC | $644.48 | 25 | $0 (2024) |
| PFIZER INC. | $569.96 | 36 | $0 (2024) |
| Eisai Inc. | $476.85 | 18 | $0 (2024) |
| Seagen Inc. | $463.34 | 17 | $0 (2023) |
| Incyte Corporation | $441.86 | 16 | $0 (2024) |
| Celgene Corporation | $400.87 | 18 | $0 (2024) |
| Daiichi Sankyo Inc. | $390.72 | 21 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $371.43 | 19 | $0 (2024) |
| GENZYME CORPORATION | $356.70 | 16 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,093 | 137 | PFIZER INC. ($294.50) |
| 2023 | $2,785 | 127 | Novartis Pharmaceuticals Corporation ($229.15) |
| 2022 | $2,670 | 136 | Novartis Pharmaceuticals Corporation ($218.57) |
| 2021 | $1,178 | 58 | Seagen Inc. ($207.29) |
| 2020 | $99.65 | 1 | Eisai Inc. ($99.65) |
| 2019 | $91.46 | 1 | Incyte Corporation ($91.46) |
| 2018 | $374.69 | 3 | Agios Pharmaceuticals, Inc. ($125.61) |
All Payment Transactions
463 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 12/17/2024 | JAZZ PHARMACEUTICALS INC. | ZIIHERA (Drug) | Food and Beverage | In-kind items and services | $20.88 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/16/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $27.68 | General |
| Category: Oncology | ||||||
| 12/16/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $26.50 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $24.31 | General |
| Category: Oncology | ||||||
| 12/12/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $27.32 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $25.13 | General |
| Category: Hematology | ||||||
| 12/09/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $19.28 | General |
| 12/06/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $17.54 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $25.35 | General |
| Category: Oncology | ||||||
| 12/03/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $2.60 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $24.97 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $20.20 | General |
| Category: BioOncology | ||||||
| 11/16/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $21.04 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $29.80 | General |
| Category: Oncology | ||||||
| 11/11/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $14.28 | General |
| 11/06/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $8.22 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/04/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $24.05 | General |
| Category: Rare Disease | ||||||
| 10/30/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $24.95 | General |
| Category: Oncology | ||||||
| 10/30/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Education | In-kind items and services | $13.04 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $14.17 | General |
| Category: BioOncology | ||||||
| 10/28/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $24.44 | General |
| Category: Oncology | ||||||
| 10/25/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $19.78 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 932 | 3,750 | $298,515 | $87,570 |
| 2022 | 24 | 834 | 8,461 | $247,715 | $60,097 |
| 2021 | 11 | 390 | 594 | $46,515 | $19,938 |
Total Patients
2,156
Total Services
12,805
Medicare Billing
$167,605
Procedure Codes
59
All Medicare Procedures & Services
59 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 142 | 322 | $51,520 | $29,890 | 58.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 20 | 135 | $87,750 | $12,168 | 13.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 43 | 43 | $13,330 | $6,960 | 52.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 74 | 97 | $11,155 | $5,417 | 48.6% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 17 | 74 | $8,510 | $5,076 | 59.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 11 | 81 | $28,350 | $3,706 | 13.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 20 | 23 | $5,175 | $3,079 | 59.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 115 | 364 | $10,920 | $3,058 | 28.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 80 | 255 | $16,575 | $2,639 | 15.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 102 | 339 | $15,255 | $2,580 | 16.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 18 | 124 | $11,780 | $2,555 | 21.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 35 | 40 | $4,600 | $2,056 | 44.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $3,185 | $1,527 | 47.9% |
| 99424 | Principal care management services for a single high-risk disease, first 30 minutes provided personally by qualified health care professional, per calendar month. | Office | 2023 | 24 | 27 | $2,940 | $1,329 | 45.2% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 40 | 52 | $4,680 | $1,309 | 28.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 16 | 29 | $4,930 | $1,274 | 25.8% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 14 | 47 | $4,700 | $773.62 | 16.5% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 40 | 40 | $1,600 | $664.95 | 41.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 20 | 50 | $2,000 | $520.50 | 26.0% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 21 | 24 | $2,400 | $320.64 | 13.4% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 16 | 17 | $1,870 | $251.26 | 13.4% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 22 | 34 | $850.00 | $201.28 | 23.7% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 15 | 1,432 | $3,560 | $145.52 | 4.1% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 14 | 88 | $880.00 | $70.41 | 8.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 134 | 325 | $37,375 | $20,201 | 54.0% |
About Dr. Devi Sampat, MD
Dr. Devi Sampat, MD is a Medical Oncology healthcare provider based in Gainesville, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/10/2015. The National Provider Identifier (NPI) number assigned to this provider is 1104212778.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Devi Sampat, MD has received a total of $10,292 in payments from pharmaceutical and medical device companies, with $3,093 received in 2024. These payments were reported across 463 transactions from 60 companies. The most common payment nature is "Food and Beverage" ($10,006).
As a Medicare-enrolled provider, Sampat has provided services to 2,156 Medicare beneficiaries, totaling 12,805 services with total Medicare billing of $167,605. Data is available for 3 years (2021–2023), covering 59 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology, Student in an Organized Health Care Education/Training Program
- Location Gainesville, GA
- Active Since 04/10/2015
- Last Updated 08/08/2022
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1104212778
Products in Payments
- KEYTRUDA (Biological) $644.48
- Lenvima (Drug) $457.31
- IMBRUVICA (Drug) $323.95
- Enhertu (Drug) $256.89
- MONJUVI (Drug) $225.27
- LIBTAYO (Biological) $225.04
- OPDIVO (Biological) $186.17
- Orserdu (Drug) $168.73
- JAKAFI (Drug) $165.49
- TIBSOVO (Drug) $159.61
- Nubeqa (Drug) $158.59
- KISQALI (Drug) $147.79
- REBLOZYL (Biological) $147.63
- VENCLEXTA (Drug) $144.94
- TALVEY (Biological) $142.04
- PADCEV (Biological) $139.99
- SARCLISA (Biological) $136.46
- PIQRAY (Drug) $131.45
- BRUKINSA (Drug) $130.72
- Udenyca (Biological) $128.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Gainesville
Dr. George Kim, M.d, M.D
Medical Oncology — Payments: $1.0M
Medical Oncology $1.0M
Dr. John Wingard, Md, MD
Medical Oncology — Payments: $147,953
Medical Oncology $147,953
Dr. Coy Heldermon, Md, MD
Medical Oncology — Payments: $47,064
Medical Oncology $47,064
Christopher Cogle, Md, MD
Medical Oncology — Payments: $33,817
Medical Oncology $33,817
Andrew Johnson, M.d, M.D
Medical Oncology — Payments: $21,882
Medical Oncology $21,882
Richard Locicero, M.d, M.D
Medical Oncology — Payments: $12,834
Medical Oncology $12,834